Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amdocs (DOX) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Amdocs (DOX) over the last 12 years, with Q3 2025 value amounting to $932000.0.

  • Amdocs' Gains from Sales and Divestitures rose 900.58% to $932000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $932000.0, marking a year-over-year increase of 900.58%. This contributed to the annual value of $932000.0 for FY2025, which is 900.58% up from last year.
  • Amdocs' Gains from Sales and Divestitures amounted to $932000.0 in Q3 2025, which was up 900.58% from $855000.0 recorded in Q3 2024.
  • Amdocs' 5-year Gains from Sales and Divestitures high stood at $932000.0 for Q3 2025, and its period low was $705000.0 during Q3 2023.
  • For the 3-year period, Amdocs' Gains from Sales and Divestitures averaged around $830666.7, with its median value being $855000.0 (2024).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 2127.66% in 2024, then soared by 900.58% in 2025.
  • Over the past 3 years, Amdocs' Gains from Sales and Divestitures (Quarter) stood at $705000.0 in 2023, then grew by 21.28% to $855000.0 in 2024, then rose by 9.01% to $932000.0 in 2025.
  • Its Gains from Sales and Divestitures was $932000.0 in Q3 2025, compared to $855000.0 in Q3 2024 and $705000.0 in Q3 2023.